The trial will test the vaccine as a monotherapy, while certain patients will also be given established chemotherapy or ... is Sanofi and Regeneron’s Libtayo (cemiplimab), a PD-L1 checkpoint ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Chemotherapy is a treatment used to kill cancer cells. It involves taking one or more of a type of drug that interferes with the DNA of fast-growing cells. These drugs are subdivided into specific ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Enel North America announced it has a power purchase agreement (PPA) for a 115-MW portion of the Rockhaven wind farm in ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Dupixent and Libtayo should be enough to offset Eylea franchise erosion and drive low to mid-single digit topline growth in 2025. 2025 should be a trough year for Regeneron's top and bottom line ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial - - Data presented at AACR 2023 supports ...